Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2B | Q13224 | 4/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.41 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.41 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.41 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.41 |
| ▸ | MAOB | P27338 | 1/20 | 0.40 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.40 |
| ▸ | DAO | P14920 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17509574 | 0.78 | CETP (0.51) | GRIN2BEPHX1DAO | |
| SCHEMBL963834 | 0.77 | PPARG (0.53) | GRIN2BALDH1A1TSHREPHX2MAPT | |
| SCHEMBL2092054 | 0.76 | SLC6A4 (0.56) | GRIN2BALDH1A1TSHREPHX2MAPT | |
| SCHEMBL254957 | 0.75 | MAPT (0.56) | ALDH1A1TSHREPHX2MAPTMAOB | |
| SCHEMBL630440 | 0.74 | MAPT (0.48) | ALDH1A1TSHREPHX2MAPTMAOB | |
| SCHEMBL155707 | 0.74 | TSHR (0.58) | GRIN2BALDH1A1TSHREPHX2MAPT | |
| SCHEMBL513288 | 0.73 | GRIN2B (0.50) | GRIN2BALDH1A1TSHREPHX2SLC6A4 | |
| SCHEMBL700042 | 0.73 | PPARA (0.56) | GRIN2BALDH1A1TSHREPHX2MAPT | |
| Ammonia Solution, Strong SCHEMBL25380785 | 0.72 | TSHR (0.56) | GRIN2BALDH1A1TSHREPHX2MAPT | |
| SCHEMBL1047224 | 0.72 | ALDH1A1 (0.47) | GRIN2BALDH1A1TSHREPHX2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115959993-A | Synthetic method of 2-aryl propionic acid compound | 山东中医药大学 | 2023-04-14 | — | — | CN | disclosed |
| EP-4038067-A1 | 4-QUINOLINONE ANTIBACTERIAL COMPOUNDS | Janssen Sciences Ireland Unlimited Company (IE) | 2022-08-10 | — | — | EP | disclosed |
| US-8828988-B2 | 8-AZA tetracycline compounds | TETRAPHASE PHARMACEUTICALS, INC. (US) | 2014-09-09 | — | — | US | disclosed |
| US-20130345178-A1 | 8-AZA Tetracycline Compounds | TETRAPHASE PHARMACEUTICALS, INC. (US) | 2013-12-26 | — | — | US | disclosed |
| EP-2427190-B1 | 8-AZA TETRACYCLINE COMPOUNDS | TETRAPHASE PHARMACEUTICALS INC (US) | 2013-09-18 | — | — | EP | disclosed |
| US-8367654-B2 | 8-AZA tetracycline compounds | TETRAPHASE PHARMACEUTICALS, INC. (US) | 2013-02-05 | — | — | US | disclosed |
| US-20120108569-A1 | 8-AZA Tetracycline Compounds | TETRAPHASE PHARMACEUTICALS, INC. | 2012-05-03 | — | — | US | disclosed |
| EP-2427190-A1 | 8-AZA TETRACYCLINE COMPOUNDS | Tetraphase Pharmaceuticals, Inc. (US) | 2012-03-14 | — | — | EP | disclosed |
| WO-2010129055-A1 | 8-AZA TETRACYCLINE COMPOUNDS | TETRAPHASE PHARMACEUTICALS, INC. (US) | 2010-11-11 | — | — | WO | disclosed |
| EP-1123296-B1 | PYRAZOLOPYRIMIDINONE cGMP PDE5 INHIBITORS FOR THE TREATMENT OF SEXUAL DYSFUNCTION | PFIZER LTD (GB) | 2003-09-17 | — | — | EP | disclosed |
| US-6333330-B1 | Pyrazolopyrimidinone CGMP PDE5 inhibitors for the treatment of sexual dysfunction | PFIZER INC. | 2001-12-25 | — | — | US | disclosed |
| EP-1123296-A1 | PYRAZOLOPYRIMIDINONE cGMP PDE5 INHIBITORS FOR THE TREATMENT OF SEXUAL DYSFUNCTION | Pfizer Limited (GB) | 2001-08-16 | — | — | EP | disclosed |
| WO-2000024745-A1 | PYRAZOLOPYRIMIDINONE cGMP PDE5 INHIBITORS FOR THE TREATMENT OF SEXUAL DYSFUNCTION | PFIZER LIMITED (GB) | 2000-05-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130345178-A1 | 8-AZA Tetracycline Compounds | TET1, TET3, HDAC8 | GRIN2B 2470/4885ALDH1A1 1338/4885TSHR 1222/4885 |
| US-20120108569-A1 | 8-AZA Tetracycline Compounds | TET1, TET3, HDAC8 | GRIN2B 2590/4885ALDH1A1 1323/4885TSHR 1184/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.